Effectiveness of Physical Measures versus Cabergoline for Lactation Inhibitio

Not Applicable

• Conditions: Other and unspecified disorders of lactation; Galactorrhoea; Suppressed lactation; O92.7; O92.6; O92.5

• Registration Number: RBR-3cbzwy
• Lead Sponsor: Instituto de Medicina Integral Prof. Fernando Figueira

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-05-08
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

Women with up to 24 hours postpartum; gestational age at delivery of 20 weeks or more; indication for inhibition of lactation: late fetal loss, neomorto up to 24 hours, breast cancer or leukemia in pregnancy or in case of severe maternal morbidity

Exclusion Criteria

Hypertensive syndromes in current gestation; known hypersensitivity to cabergoline; history of cardiac valve disease;
history of retroperitoneal or pulmonary fibrotic disease

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severe breast pain is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms;Severe engorgement is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms;Severe spontaneous papillary discharge is expected to occur in less than 10% of patients. Measurement scale will determine the intensity of the symptoms

Secondary Outcome Measures

Name	Time	Method
Decreased frequency of adverse effects to less than 1%. Adverse effects will be investigated through interviews;Decreased complications to less than 1%. Complications will be assessed through clinical examination;There will be no change in blood pressure. Blood pressure will be measured before and one hour after the intervention